Effect of Ticagrelor Versus Clopidogrel on Endothelial Dysfunction and Vascular Inflammation

NCT ID: NCT02379676

Last Updated: 2016-07-06

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 38 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-01-31
• Study Completion Date: 2017-03-31

Brief Summary

The purpose of this study is to compare the effects of ticagrelor and clopidogrel on endothelial dysfunction and vascular inflammation

Ticagrelor will lead to beneficial pleiotropic effects compared with treatment with clopidogrel in patients receiving a drug-eluting stents (DES) during percutaneous coronary intervention (PCI) for non-ST-segment acute coronary syndrome (NSTE-ACS) beyond 1 month after the index event. Ticagrelor treatment will improve percent flow-mediated dilation (FMD) values and reduces inflammatory gene expression on peripheral blood mononuclear cells.

Detailed Description

The primary objective of this study lies in whether ticagrelor improves endothelial dysfunction compared to clopidogrel, measured by endothelium-dependent flow-mediated dilation (FMD). The secondary objective is to demonstrate whether ticagrelor has an anti-atherosclerotic effect compared to clopidogrel in terms of reducing systemic low-grade inflammation. Endpoints are 1) difference of flow-mediated dilation values, and 2) messenger ribonucleic acid (mRNA) expression measured by quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) of inflammation-associated key genes in circulation monocytes between non-ST-segment acute coronary syndrome patients treated with ticagrelor and clopidogrel.

Patients who agree to participate study are screened at Visit 1 (30 ~ 365 days after index percutaneous coronary intervention). Patients with endothelial dysfunction defined as screening flow-mediated dilation are randomly assigned at Visit 2 (0~7 days after screening test). And then, patients should receive study drugs according to allocated groups from the day of randomization. Ticagrelor 90mg twice daily or clopidogrel 75mg daily will be maintained for 30 days. Flow-mediated dilation are performed at screening and at Visit 3 (day 30 from the treatment of study drugs) and blood sampling are performed before the first dose of study drugs at Visit 2 and at Visit 3.

Conditions

Endothelial Dysfunction; Vascular Inflammation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Ticagrelor

Ticagrelor 90mg twice daily

Group Type: EXPERIMENTAL

Ticagrelor

Intervention Type: DRUG

Ticagrelor 90mg twice daily for 30 days

Clopidogrel

Clopidogrel 75mg once daily

Group Type: ACTIVE_COMPARATOR

Clopidogrel

Intervention Type: DRUG

Clopidogrel 75mg once daily for 30 days

Interventions

Ticagrelor

Ticagrelor 90mg twice daily for 30 days

Intervention Type: DRUG

Clopidogrel

Clopidogrel 75mg once daily for 30 days

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Provision of informed consent prior to any study specific procedures
• Men and women ≥20 years of age
• Documented history of non-ST-segment acute coronary syndrome occurring 30 ~ 365 days prior to randomization and successfully treated with percutaneous coronary intervention using drug-eluting stent
• Patient currently prescribed and tolerating aspirin 100mg and clopidogrel 75mg.
• Patient who have demonstrated endothelial dysfunction defined as percent flow-mediated dilation values lower than 7% at baselines test

Exclusion Criteria

• Patients with angina related symptoms
• Patients who did not undergo or failed invasive treatment
• Patients with a history of hypersensitivity to ticagrelor or clopidogrel
• Patients who took an anti-coagulant, anti-thrombotic regularly before the study, or plan to have continuous treatment during the study
• Patients who took vasoactive agents or caffeine ingestion for <48
• Patients with decompensated congestive heart failure of cardiogenic shock (Killip classification III or IV)
• Patients with intractable arrhythmia
• Patients with intractable arrhythmia
• Patients with second or third degree atrioventricular block
• Patients with uncontrolled hypertension
• Patients with high risk of hemorrhage like blood coagulation disorders, gastrointestinal bleeding, gross hematuria, intraocular bleeding, hemorrhagic stroke, intracranial hemorrhage
• Patients with more than moderate chronic obstructive pulmonary disease diagnosed by symptoms or documented by pulmonary function test
• Patients who required renal replacement therapy
• Patients with moderate to severe hepatic impairment
• Patients with platelet <100,000/μL
• Patients with hematocrit <30%
• Concomitant oral or parenteral therapy with strong cytochrome P450 3A4 inhibitors, cytochrome P450 3A substrates with narrow therapeutic indices, or strong cytochrome P450 3A4 inducers i) Strong inhibitors: ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin (but not erythromycin or azithromycin), nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atanazavir, over 1 litre daily of grapefruit juice ii) Substrates with narrow therapeutic index: cyclosporine, quinidine, simvastatin at doses >40 mg daily or lovastatin at doses >40 mg daily iii) Strong inducers: rifampin/rifampicin, rifabutin, phenytoin, carbamazepine, phenobarbital
• Patient who need to take drugs other than study medications and allowed concomitant medications during study period.
• Patients who have planned elective surgery or invasive procedure requiring temporary discontinued study medication during study period.
• Patients who are pregnant, breast feeding and not using medically acceptable birth control.
• Patients considered as unsuitable based on medical judgment by investigators.

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: collaborator

Kiyuk Chang

OTHER

Sponsor Role: lead

Responsible Party

Kiyuk Chang

Chief of the divison of cardiology

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Kiyuk Chang, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Seoul St. Mary's Hospital, The Catholic.University of Korea

Locations

Seoul St. Mary's Hospital, The Catholic University of Korea

Seoul, , South Korea

Site Status: RECRUITING

Countries

South Korea

Central Contacts

Kiyuk Chang, MD, PhD

Role: CONTACT

kiyuk@catholic.ac.kr

82-2-2258-1139

Sungmin Lim, MD

Role: CONTACT

sungmin@catholic.ac.kr

82-2-2258-1139

Facility Contacts

Kiyuk Chang, MD, PhD

Role: primary

kiyuk@catholic.ac.kr

82-2-2258-1139

Sungmin Lim, MD

Role: backup

sungmin@catholic.ac.kr

82-2-2258-1139

Other Identifiers

XC14MIMI0092k

Identifier Type: -

Identifier Source: org_study_id